the Value of Immunohistochemical Expression of Moesin in Endometrial Hyperplasia and Endometrial Carcinoma

Not yet recruiting

• Conditions: Endometrial Cancer and Endometrial Hyperplasia
• Interventions: Device: microscopic pathological evaluation

• Registration Number: NCT05619159
• Lead Sponsor: Sohag University

Brief Summary

Endometrial carcinoma (EC) is the most prevalent invasive carcinoma of the female genital tract in developed countries, while it ranks as the second most frequently occurring neoplasm of women in developing countries, after carcinoma of the cervix uteri. The vast majority of ECs occur in perimenopausal and postmenopausal women .

ECs are classified into two distinct phenotypes; type I which represents more than 80% of all cases of ECs, it has a favorable prognosis. This type is linked to excess, unopposed hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia. On the contrary, type II endometrial carcinoma is less common than type I, representing less than 10% of all cases of ECs. Type II endometrial carcinomas are high grade, poorly differentiated and estrogen-independent tumors .

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2022-10-23
• Status Verified: 2022-11
• Study Start: 2022-11
• Study First Submitted QC: 2022-11-08
• Last Update Submitted: 2022-11-08
• Study First Posted: 2022-11-16
• Last Update Posted: 2022-11-16
• Primary Completion: 2023-05
• Study Completion: 2023-05

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• Hysterectomy specimens diagnosed as endometrial hyperplasia and endometrial adenocarcinoma.
• All cases of endometrial biopsies obtained by curettage (D&C) diagnosed as endometrial hyperplasia.
• Cases of cyclical endometrium obtained from endometrial curettage or hysterectomy specimens done for pathological conditions other than hyperplastic or neoplastic endometrial lesions.
• Complete clinical data.

Read More

Exclusion Criteria

• Patients with a history of preoperative chemotherapy and /or radiotherapy.
• Biopsies with predominantly blood clots.
• Insufficient or tiny tissue biopsies.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
endometrial hyperplasia samples	microscopic pathological evaluation	-
endometrial carcinoma smples	microscopic pathological evaluation	-

Primary Outcome Measures

Name	Time	Method
The value of immunohistochemical expression of moesin in endometrial hyperplasia and endometrial carcinoma	1 year	To evaluate immunohistochemical expression of moesin in normal, hyperplasic and neoplastic endometrial tissues , correlate this expression with different clinicopathologic parameters of endometrial carcinoma and to evaluate the role of moesin as prognostic marker in progression from preinvasive lesions of the endometrium to endometrial carcinoma.

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt